$1.96 +0.10 (%) Galectin Therapeutics Inc - NASDAQ

Aug. 28, 2015 | 04:00 PM

Partner Headlines

  1. Mid-Day Market Update: Thursday's Movers, China, Tesla And More

    Benzinga | Aug. 13, 2015 | 13:09PM EST
  2. Morning Market Gainers

    Benzinga | Aug. 13, 2015 | 09:45AM EST
  3. Morning Market Gainers

    Benzinga | Jan. 7, 2015 | 09:38AM EST
  4. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 24, 2014 | 10:12AM EST
  5. MLV & Co Has Positive Outlook On Galectin Therapeutics Inc

    Benzinga | Sep. 16, 2014 | 09:56AM EST
  6. UPDATE: Aegis Capital Downgrades Galectin Therapeutics

    Benzinga | Aug. 1, 2014 | 12:26PM EST
  7. Galectin Issues Statement on Yesterday's Sell Off, Says Attributed To Negative Social Media Posts and Misinterpretation

    Benzinga | Jul. 30, 2014 | 09:09AM EST
  8. Morning Market Losers

    Benzinga | Jul. 29, 2014 | 09:54AM EST
  9. Galectin Offers Results in Preclinical Model of GR-MD-02, Results Show Significant Disease Improvement

    Benzinga | Jun. 23, 2014 | 08:06AM EST
  10. Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02

    Benzinga | Apr. 23, 2014 | 08:02AM EST
  11. Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis; Exoects GR-MD-02 Phase 1 Cohort 2 Result at End of July

    Benzinga | Apr. 17, 2014 | 10:23AM EST
  12. MLV & Co Expects Positive News from Galectin Therapeutics

    Benzinga | Apr. 1, 2014 | 09:03AM EST
  13. Benzinga's Volume Movers

    Benzinga | Mar. 25, 2014 | 10:26AM EST
  14. Fatty Liver Disease Should Keep Stocks Moving In 2014

    IBD | Mar. 7, 2014 | 17:02PM EST
  15. Galectin Therapeutics Complet Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Patients with NASH

    Benzinga | Jan. 13, 2014 | 08:05AM EST
  16. Market Wrap For January 10: Job Growth Weak, But Unemployment Falls

    Benzinga | Jan. 10, 2014 | 16:53PM EST
  17. Benzinga's Volume Movers

    Benzinga | Jan. 10, 2014 | 10:26AM EST
  18. Galectin Announces Early Warrant Exercise by 10X Fund, Issues Update on Cash Position

    Benzinga | Oct. 17, 2013 | 08:09AM EST
  19. UPDATE: Ascendiant Capital Initiates Coverage on Galectin Therapeutics on Intriguing Speculative Short-Cap Investment Story

    Benzinga | Oct. 7, 2013 | 10:55AM EST
  20. Benzinga's Top Initiations

    Benzinga | Oct. 7, 2013 | 07:49AM EST
  21. Benzinga's Volume Movers

    Benzinga | Sep. 12, 2013 | 10:43AM EST
  22. Morning Market Movers

    Benzinga | Sep. 12, 2013 | 10:11AM EST
  23. Benzinga's Volume Movers

    Benzinga | Sep. 11, 2013 | 10:45AM EST
  24. UPDATE: Aegis Capital Raises PT on Galectin Therapeutics Following Valuation Update

    Benzinga | Aug. 19, 2013 | 11:26AM EST
  25. Morning Market Movers

    Benzinga | Aug. 12, 2013 | 10:13AM EST
  26. Galectin Therapeutics Reports FDA Fast Track Designation for GR-MD-02

    Benzinga | Aug. 12, 2013 | 08:04AM EST
  27. Galectin Therapeutics Says Anti-Galectin Drug Effective in Preclinical Studies

    Benzinga | Jan. 22, 2013 | 02:04AM EST
  28. Galectin Therapeutics Names Shlevin COO

    Benzinga | Aug. 29, 2012 | 03:01AM EST
  29. Galectin Therapeutics Receives U.S. Patent for Potential Ground-Breaking Treatment for Chronic Liver Disease with Fibrosis and Cirrhosis

    Benzinga | Jul. 23, 2012 | 03:48AM EST
  30. UPDATE: Dawson James Reiterates Buy Rating, Lowers PT on Galectin Therapeutics

    Benzinga | Jul. 6, 2012 | 05:00AM EST
  31. ProShares Trust Ultra VIX Short Term Futures ETF, CTC Media Among Stocks hitting 52-Week Lows Tuesday

    FoxBusiness | Jul. 3, 2012 | 06:31AM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!